JPRN-UMIN000013169已完成1 期
Phase I/II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly VRd-21) for relapsed and/or refractory multiple myeloma (Once weekly VRd-21, I/II VRD for MM) - Phase I/II study of once weekly VRd-21 for relapsed and/or refractory multiple myeloma (Once weekly VRd-21, I/II VRD for MM)
agoya City University Hospital0 个研究点目标入组 30 人开始时间: 2014年2月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) synchronous or metachronous malignancy 2) active infection 3) severe constipation or illeus 4) interstitial pneoumonia, pulmonary fibrosis 5) uncontrolled diabetes 6) inability to intake antithrombotic medication 7) pregnant or nursing women mellitus 8) uncontrollable hypertension 9) psychological disturbance 10) active double cancer 11) HBs-Ag positive or HCV-Ab positive or HIV-Ab positive 12) grade 3 or higher peripheral neuropathy, or grade 1 or higher neuralgia 13) glaucoma 14) primary plasma cell leukemia 15) no adminstration of blood transfusion or G-CSF within 7days befor the treatment 16) no evidence of cardiac or intestinal amyloidosis 17) allergic history to borate or mannitol
研究者
相似试验
进行中（未招募）
不适用
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in elderly patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma - HOVON 86 MMMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomamultiple myelomaEUCTR2007-002533-37-NLHOVON Foundation84
进行中（未招募）
1 期
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in elderly patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma - HOVON 86 MMMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomamultiple myelomaEUCTR2007-002533-37-BEHOVON Foundation84
已完成
2 期
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in elderly patients in 1st relapse or primary refractory after first line therapy for multiple myeloma.Kahlers disease10035227multiple myelomaNL-OMON33820HOVO68
招募中
不适用
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma.NL-OMON23532Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 704102872
进行中（未招募）
不适用
Randomized phase II study of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in elderly patients with newly diagnosed multiplemyelomaKCT0004508Samsung Medical Center126